User menu

Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.

Bibliographic reference Delgrange, Etienne ; Duprez, Thierry ; Maiter, Dominique. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.. In: Clinical Endocrinology, Vol. 64, no. 4, p. 456-462 (2006)
Permanent URL
  1. Ahmadi J, North CM, Segall HD, Zee CS, Weiss MH, Cavernous sinus invasion by pituitary adenomas, 10.2214/ajr.146.2.257
  2. Fahlbusch R., Buchfelder M., Transsphenoidal surgery of parasellar pituitary adenomas, 10.1007/bf01401978
  3. Knosp E., Neurosurgery, 33, 610 (1993)
  4. Cottier Jean-Philippe, Destrieux Christophe, Brunereau Laurent, Bertrand Philippe, Moreau Laurence, Jan Michel, Herbreteau Denis, Cavernous Sinus Invasion by Pituitary Adenoma: MR Imaging, 10.1148/radiology.215.2.r00ap18463
  5. Doniack I., Clinical Endocrinology, 37, 194 (1992)
  6. Kaltsas Gregory A., Nomikos Panagiotis, Kontogeorgos George, Buchfelder Michael, Grossman Ashley B., Diagnosis and Management of Pituitary Carcinomas, 10.1210/jc.2004-2231
  7. Saeki N., Iuchi T., Isono S., Eda M., Yamaura A., MRI of growth hormone-secreting pituitary adenomas: factors determining pretreatment hormone levels, 10.1007/s002340050839
  8. Delgrange E., Sassolas G., Perrin G., Jan M., Trouillas J., Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance, 10.1007/s00701-005-0498-2
  9. Pan Li-xiong, Chen Zhong-ping, Liu Yun-sheng, Zhao Ji-hong, Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space, 10.1007/s11060-004-6150-9
  10. Losa M., Surgical Treatment of Prolactin-Secreting Pituitary Adenomas: Early Results and Long-Term Outcome, 10.1210/jc.87.7.3180
  11. Verhelst J., Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients, 10.1210/jc.84.7.2518
  12. Delgrange E., European Journal of Endocrinology, 134, 454 (1996)
  13. Di Sarno A., Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy, 10.1210/jc.86.11.5256
  14. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  15. Gandour-Edwards R., Modern Pathology, 8, 160 (1995)
  16. Jaffrain-Rea M., A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas, 10.1677/erc.0.0090103
  17. Corsello S. M., Ubertini G., Altomare M., Lovicu R. M., Migneco M. G., Rota C. A., Colosimo C., Giant prolactinomas in men: efficacy of cabergoline treatment, 10.1046/j.1365-2265.2003.01770.x
  18. Colao Annamaria, Di Sarno Antonella, Cappabianca Paolo, Di Somma Carolina, Pivonello Rosario, Lombardi Gaetano, Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia, 10.1056/nejmoa022657
  19. Brue T., Hormone Research, 38, 84 (1992)
  20. Delgrange E., Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study, 10.1210/jc.82.7.2102
  21. Colao Annamaria, Vitale Giovanni, Cappabianca Paolo, Briganti Francesco, Ciccarelli Antonio, De Rosa Michele, Zarrilli Stefano, Lombardi Gaetano, Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis, 10.1210/jc.2003-030979
  22. Pellegrini I., Journal of Clinical Endocrinology and Metabolism, 69, 500 (1989)
  23. Caccavelli L., Hormone Research, 38, 78 (1992)
  24. Hofland L.J., Frontiers of Hormone Research, 32, 235 (2004)
  25. Ren Song-Guang, Kim Sun, Taylor John, Dong Josse, Moreau Jacques-Pierre, Culler Michael D., Melmed Shlomo, Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand, 10.1210/jc.2003-030302